13F HOLDINGS REPORT
Aisling Capital Management LP
Quarter ended Q1 2024 · Filed May 14, 2024 · Accession 0001766721-24-000003
Total Value
$295.5M
Positions
16
Other Managers
0
Confidential Omitted
No
Holdings (16)
| # | Issuer | Ticker / CUSIP | Shares | Value | % of Filing |
|---|---|---|---|---|---|
| 1 | BridgeBio Pharma Inc. (BBIO) | BBIO | 6,068,125 | $187.6M | 63.50% |
| 2 | Syndax Pharmaceuticals, Inc. (SNDX) | SNDX | 1,025,000 | $24.4M | 8.26% |
| 3 | Verona Pharma plc (VRNA) | 925050106 | 1,115,352 | $17.9M | 6.07% |
| 4 | Elevation Oncology Inc (ELEV) | 28623U101 | 2,834,910 | $14.5M | 4.92% |
| 5 | Biomea Fusion Inc (BMEA) | BMEA | 798,757 | $11.9M | 4.04% |
| 6 | Monte Rosa Therapeutics Inc (GLUE) | GLUE | 1,472,331 | $10.4M | 3.51% |
| 7 | Nuvation Bio Inc. (NUVB) | NUVB | 2,541,009 | $9.2M | 3.13% |
| 8 | Compass Pathways Plc (CMPS) | CMPS | 964,500 | $8.0M | 2.72% |
| 9 | Poseida Therapeutics Inc. (PSTX) | 73730P108 | 1,043,267 | $3.3M | 1.13% |
| 10 | CalciMedica, Inc. (CALC) | CALC | 521,114 | $2.2M | 0.73% |
| 11 | Reneo Pharmaceuticals Inc (RPHM) | 75974E103 | 886,075 | $1.5M | 0.50% |
| 12 | Marker Therapeutics, Inc. (MRKR) | MRKR | 314,286 | $1.4M | 0.46% |
| 13 | Avrobio, Inc. (AVRO) | 05455M100 | 1,009,779 | $1.3M | 0.44% |
| 14 | Spruce Biosciences, Inc. (SPRB) | SPRB | 1,205,511 | $947,532 | 0.32% |
| 15 | Aclaris Therapeutics Inc (ACRS) | ACRS | 434,455 | $538,724 | 0.18% |
| 16 | Viracta Therapeutics Inc (VIRX) | 92765F108 | 288,571 | $294,342 | 0.10% |